Lesson
Pulmonary Injury Patterns and Mechanisms
Drug-induced pulmonary disease is a family of phenotypes, not one radiographic diagnosis. The same medicine can create more than one pattern, and the same pattern can arise from many competing causes.
- Airway injury
- Interstitial and alveolar injury
- Vascular and pleural disease
- Respiratory control
- Direct, immune, and cumulative mechanisms
Irritation, mediator accumulation, or smooth-muscle effect
Organizing, interstitial, eosinophilic, or alveolar injury
Pressure, edema, bleeding, weakness, or depressed drive
Map the affected compartment
Medication injury may present as cough, bronchospasm, bronchiolitis, organizing pneumonia, cellular or fibrotic interstitial disease, eosinophilic pneumonia, diffuse alveolar damage, noncardiogenic edema, alveolar hemorrhage, pleural effusion, pulmonary vascular disease, respiratory-muscle weakness, or central hypoventilation. CT appearance describes a pattern but rarely names the drug.
Separate inflammation from established fibrosis
Acute inflammatory or hypersensitivity injury can improve rapidly after withdrawal and selected corticosteroid treatment. Chronic exposure can produce organizing inflammation, phospholipid accumulation, or irreversible fibrosis. Symptoms, oxygenation, serial imaging, spirometry, diffusion, and trajectory help distinguish active injury from residual scar.
Connect mechanism to exposure
Direct cytotoxicity can relate to cumulative exposure, reactive metabolites, oxidative injury, tissue retention, or impaired clearance. Immune injury may occur after a shorter or variable latency and can recur rapidly with re-exposure. Vascular, cardiac, coagulation, neuromuscular, and central nervous system effects can mimic primary parenchymal toxicity.
Treat severity as a separate axis
A small asymptomatic opacity and rapidly progressive hypoxemic respiratory failure can share a suspected agent but demand different action. Record oxygen requirement, respiratory rate, work of breathing, hemodynamics, CT extent, functional limitation, and organ support. Stabilization should not wait for perfect causal certainty.
Quick check
Checking for saved practice…
Lesson
Exposure Reconstruction, Diagnosis, and Causality
Diagnosis rests on a compatible exposure and phenotype, reasonable latency, exclusion of better explanations, and a response trajectory. No isolated test proves medication causality.
- Complete exposure history
- Latency and dose
- Competing diagnoses
- CT, PFT, BAL, and biopsy
- Dechallenge and rechallenge
Start, stop, dose, cycle, organ function, and procedure
Infection, edema, embolism, tumor, radiation, and disease
Recovery after withdrawal supports but does not prove causality
Reconstruct every relevant exposure
Include prescriptions, inhaled products, chemotherapy cycles, immunotherapy, radiation, supplements, illicit substances, occupational exposure, oxygen concentration, anesthesia, transfusion, and recent procedures. Record start, stop, dose, cumulative exposure, renal and hepatic function, prior use, and symptom onset. A current medication list without dates cannot support causality.
Use latency as evidence, not a rigid rule
Acute hypersensitivity can emerge within hours or days, while cumulative injury may appear after months or years. Toxicity can begin after a drug is stopped when tissue retention or immune activation persists. Prior tolerance does not exclude a new reaction, and prior sensitization can shorten recurrence.
Actively exclude common mimics
Evaluate infection, heart failure, fluid overload, pulmonary embolism, cancer progression, lymphangitic spread, radiation injury, aspiration, diffuse alveolar hemorrhage, connective-tissue disease, and exacerbation of underlying lung disease. Use cultures, viral testing, ECG, biomarkers, echocardiography, CT angiography, bronchoscopy, or other studies when the result would change care.
Use dechallenge as longitudinal evidence
Improvement after withdrawal supports causality, but concurrent antibiotics, diuresis, corticosteroids, cancer response, or spontaneous change can confound interpretation. Delayed recovery can reflect tissue persistence or fibrosis. Diagnostic rechallenge is rarely justified when recurrence could be severe.
Quick check
Checking for saved practice…
Lesson
Clinical Assessment, Testing, and Monitoring
Testing should define physiology, severity, alternatives, and trajectory. Imaging, pulmonary function, bronchoscopy, pathology, and laboratory findings contribute different pieces rather than one confirmatory answer.
- Patient care process
- Imaging pattern and extent
- Pulmonary physiology
- Bronchoscopy and pathology
- Baseline and follow-up monitoring
Use radiography and CT to localize disease and alternatives
Trend oxygen, ventilation, spirometry, volumes, and diffusion
Use lavage or biopsy only when the result can change care
Collect a decision-ready baseline
Document respiratory symptoms, activity, oxygenation, examination, smoking and occupational exposure, prior lung disease, treatment indication, dose, duration, organ function, interacting therapy, radiation, procedures, and available chest imaging or pulmonary function. Baseline testing is product and risk specific rather than universal.
Use imaging to define pattern and extent
Chest radiography can reveal new disease and major alternatives, while high-resolution CT better defines distribution, ground-glass change, consolidation, nodules, air trapping, edema, hemorrhage, and fibrosis. Imaging can support a compatible phenotype but rarely identifies the culprit by itself.
Measure physiology and gas exchange
Pulse oximetry, exertional testing, blood gas analysis when ventilation is uncertain, spirometry, lung volumes, and diffusing capacity quantify different consequences. Serial change can be more informative than one value. A normal early test does not exclude evolving toxicity when symptoms are concerning.
Reserve invasive testing for a decision
Bronchoalveolar lavage can evaluate infection, hemorrhage, eosinophilia, and inflammatory patterns. Biopsy can clarify unresolved disease when the result is likely to change treatment and procedural risk is acceptable. Neither a nonspecific cell profile nor histologic pattern automatically proves medication causality.
Quick check
Checking for saved practice…
Lesson
Classic Pulmonary Toxicants
Amiodarone, nitrofurantoin, methotrexate, and bleomycin illustrate tissue retention, hypersensitivity, immune injury, cumulative toxicity, and patient-specific susceptibility.
- Amiodarone
- Nitrofurantoin
- Methotrexate
- Bleomycin
- Risk and monitoring
Tissue persistence, phospholipidosis, inflammation, and fibrosis
Acute hypersensitivity or subacute immune pneumonitis
Dose, kidney function, age, radiation, and oxygen context
Respect amiodarone tissue persistence
Amiodarone can cause subacute pneumonitis, organizing pneumonia, diffuse alveolar damage, nodules, or fibrosis. Risk rises with exposure, age, lung disease, thoracic surgery, and high inspired oxygen contexts, but toxicity can occur at lower doses. Baseline chest imaging and PFT information support later comparison. Stop suspected therapy, stabilize the arrhythmia plan, and recognize that the long half-life can delay improvement.
Separate acute and chronic nitrofurantoin reactions
Acute nitrofurantoin pulmonary hypersensitivity can produce fever, cough, dyspnea, infiltrates, and sometimes eosinophilia within days. Chronic pneumonitis and fibrosis emerge after prolonged exposure, often during prophylaxis. Renal function, duration, age, new respiratory symptoms, and continuing indication require review. Immediate withdrawal is central.
Treat methotrexate pneumonitis as a diagnosis of exclusion
Methotrexate pneumonitis can present with cough, dyspnea, fever, hypoxemia, and diffuse opacities, sometimes early and without a cumulative-dose relationship. Infection, rheumatoid or inflammatory lung disease, edema, and other immunosuppressant toxicity remain active alternatives. Stop methotrexate and coordinate corticosteroid treatment according to severity after the infectious evaluation.
Anticipate bleomycin lung injury
Bleomycin can produce pneumonitis and fibrosis, with risk influenced by cumulative dose, age, renal function, prior or concurrent thoracic radiation, other therapy, and oxygen exposure. Monitor symptoms and lung trajectory rather than relying on one threshold to guarantee safety. Stop suspected bleomycin and coordinate oncology, pulmonary, and perioperative oxygen planning.
Quick check
Checking for saved practice…
Lesson
Cancer Therapy and Immune Pneumonitis
Cancer treatment can injure lung through cytotoxic, immune, targeted, radiation, infectious, volume, and tumor-related mechanisms that frequently coexist.
- Checkpoint pneumonitis
- CTCAE severity
- Steroid strategy
- Targeted therapy
- Radiation and combination injury
Asymptomatic and limited with repeat assessment
Prednisone, prolonged taper, and 48 to 72 hour check
Permanent stop, IV steroid, and rescue immunosuppression
Recognize checkpoint inhibitor pneumonitis
PD-1, PD-L1, and CTLA-4 pathway therapy can cause focal or diffuse pneumonitis with cough, dyspnea, oxygen need, chest pain, fever, or asymptomatic CT findings. Organizing pneumonia, ground-glass, hypersensitivity, and diffuse alveolar damage patterns can occur. No clinical, radiographic, or pathologic feature is pathognomonic, so infection, embolism, radiation, tumor, and edema require evaluation.
Link ASCO grade to action
Grade 1 is asymptomatic and limited. Management can include holding therapy or close monitoring with repeat imaging. Grade 2 is symptomatic and generally requires holding immunotherapy, prednisone 1 to 2 mg per kg daily, a four to six week taper, and reassessment within 48 to 72 hours. Grade 3 or 4 requires hospitalization, permanent discontinuation, IV methylprednisolone, multidisciplinary care, and additional immunosuppression if refractory.
Treat refractory disease without forgetting infection
Failure to improve after 48 to 72 hours at Grade 2 triggers Grade 3 management. Severe disease without response after about 48 hours can prompt mycophenolate, IVIG, infliximab, or cyclophosphamide under specialist direction. Before deeper immunosuppression, reassess cultures, bronchoscopy when feasible, opportunistic infection risk, prophylaxis, glucose, bone, GI, psychiatric, and thrombotic steroid effects.
Separate immune toxicity from the cancer context
Tumor progression, lymphangitic spread, radiation change, infection, embolism, edema, transfusion, and other anticancer agents can coexist with immune pneumonitis. Reassess the differential when corticosteroid response is absent or incomplete rather than escalating immunosuppression automatically.
Quick check
Checking for saved practice…
Lesson
Antibody-Drug Conjugates and Targeted Therapy
Modern oncology products carry molecule-specific lung warnings. Recognition and management must follow the exact current label rather than borrowing one universal pneumonitis algorithm.
- Antibody-drug conjugate risk
- Enhertu
- Datroway
- Targeted and mTOR therapy
- Radiation interaction
Investigate cough, dyspnea, fever, or new imaging promptly
Separate conjugate, kinase, mTOR, cytotoxic, and radiation risk
Hold, treat, discontinue, or reconsider only by product rule
Treat the product label as the operational rule
Antibody-drug conjugates, tyrosine kinase inhibitors, mTOR inhibitors, cytotoxic agents, and growth factors can cause interstitial lung disease or pneumonitis. Incidence, grading language, required monitoring, dose interruption, and permanent discontinuation differ by product and indication.
Recognize deruxtecan payload risk early
Fam-trastuzumab deruxtecan and datopotamab deruxtecan can cause severe or fatal interstitial lung disease and pneumonitis. Teach patients to report new cough, dyspnea, fever, or worsening respiratory symptoms immediately. Prompt investigation matters because mild symptoms can precede clinically important injury.
Do not generalize rechallenge rules
Current Enhertu labeling requires permanent discontinuation for Grade 2 or higher interstitial lung disease or pneumonitis. Datroway has its own grade-specific interruption, treatment, and discontinuation instructions. Verify the current label at every event because oncology labeling changes as evidence and indications expand.
Integrate radiation and combination exposure
Thoracic radiation can produce time- and field-related injury, while sequential or combined systemic therapy can alter risk and pattern. Map the radiation field, treatment dates, cumulative exposure, prior events, tumor location, and concurrent agents before attributing a new opacity to one cause.
Quick check
Checking for saved practice…
Lesson
Airway, Vascular, Pleural, and Ventilatory Toxicity
Not every medication-related respiratory problem is pneumonitis. Cough, bronchospasm, pulmonary vascular disease, edema, hemorrhage, effusion, weakness, and hypoventilation require different mechanisms and responses.
- ACE inhibitor cough
- Bronchospasm
- Pulmonary hypertension
- Edema and hemorrhage
- Hypoventilation and weakness
Remove mediator or trigger and restore airflow
Evaluate PAH, thrombus, hemorrhage, and edema
Support airway and carbon dioxide clearance
Distinguish cough from parenchymal injury
ACE inhibitors can increase bradykinin and substance P and cause a dry cough that resolves after withdrawal, sometimes over weeks. Inhaled powders or aerosols can irritate airways. Cough still requires evaluation when red flags, hypoxemia, fever, focal findings, hemoptysis, or an incompatible timeline suggests another cause.
Recognize medication-triggered bronchospasm
Nonselective beta blockade can worsen airflow limitation, while aspirin and NSAIDs can trigger respiratory reactions in susceptible patients with asthma and nasal polyps. Aerosol therapy can also provoke acute bronchospasm. Treat the immediate airway event, remove the trigger when appropriate, and preserve evidence-based cardioselective beta blockade when the patient can safely receive it.
Look for vascular and fluid mechanisms
Some drugs cause pulmonary arterial hypertension, chronic thromboembolic risk, vasoconstriction, capillary leak, cardiogenic edema, or diffuse alveolar hemorrhage. Dasatinib-associated pulmonary hypertension and pleural effusion, appetite-suppressant or stimulant exposure, anticoagulant bleeding, transfusion reactions, and drug-related cardiac dysfunction require mechanism-specific evaluation.
Protect ventilation and muscle function
Opioids, sedatives, anesthetics, gabapentinoids with depressants, and neuromuscular blockers can suppress respiratory drive or airway protection. Corticosteroids, hydroxychloroquine, statins, colchicine, and other agents can contribute to myopathy in selected settings. Check ventilation, carbon dioxide, mental status, airway, strength, drug combinations, renal function, and reversal options rather than labeling the problem pneumonitis.
Quick check
Checking for saved practice…
Lesson
Withdrawal, Treatment, Rechallenge, and Prevention
Safe management stops the likely cause while preserving the disease plan, treats the current physiology, documents evidence, and prevents accidental re-exposure.
- Stabilization and withdrawal
- Corticosteroid selection
- Follow-up trajectory
- Rechallenge decisions
- Pharmacovigilance and prevention
Oxygen, ventilation, infection, edema, or airway support
Symptoms, oxygen, imaging, function, and taper response
Culprit, phenotype, severity, re-exposure plan, and alternatives
Stabilize and withdraw with a replacement plan
Support oxygenation and ventilation, stop the likely culprit when benefit-risk permits, and address infection, edema, embolism, hemorrhage, or airway disease in parallel. Abruptly stopping antiarrhythmic, antiseizure, immunosuppressive, or cancer therapy can create new harm, so coordinate substitution and monitoring rather than merely deleting the drug.
Use corticosteroids for the right phenotype
Systemic corticosteroids are common for clinically significant immune or inflammatory pneumonitis, but dose and taper depend on severity, culprit, evidence, and response. They do not treat established fibrosis, fluid overload, embolism, bacterial infection, or isolated ACE inhibitor cough. Before prolonged therapy, plan infection prophylaxis when indicated and monitor glucose, bone, GI, psychiatric, and muscle effects.
Measure recovery and detect relapse
Follow symptoms, oxygen, activity, imaging, spirometry, DLCO, inflammatory markers when useful, and the underlying disease. Worsening during taper can reflect recurrent inflammation, infection, embolism, edema, or an insufficient taper. Persistent imaging alone does not always equal active inflammation, especially when fibrosis remains.
Make rechallenge an explicit high-stakes decision
Consider severity, certainty, alternative treatments, expected benefit, reversibility, recurrence lethality, prior response, patient goals, and current label. Severe checkpoint pneumonitis, bleomycin fibrosis, or a convincing dangerous re-exposure history generally argues against rechallenge. Document the culprit, phenotype, date, evidence, plan, counseling, allergy or intolerance record, and adverse-event report.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 120 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.